You might also like
Lantheus Holdings, Inc. is a leading radiopharmaceutical-focused company dedicated to delivering life-changing science to enable clinicians to "Find, Fight and Follow" disease, ultimately improving patient outcomes. The company specializes in developing and marketing products that assist healthcare professionals in detecting, treating, and monitoring diseases, with a strong focus on oncology and cardiology. Lantheus sells its products primarily in the United States and also distributes internationally through direct and third-party channels.
- Radiopharmaceutical Oncology - Develops and markets products for detecting, treating, and monitoring cancer, with a focus on prostate cancer. Key products include PYLARIFY, a leading diagnostic agent in this category .
- Precision Diagnostics - Provides diagnostic information to help healthcare professionals detect and characterize diseases, primarily in cardiology. Notable products include DEFINITY, an ultrasound enhancing agent, and other nuclear imaging products like TechneLite and Xenon .
- Strategic Partnerships and Other Revenue - Engages in out-licensing arrangements and partnerships to enable precision medicine through biomarkers, digital solutions, and radiotherapeutic platforms. This includes products like MK-6240 and NAV-4694 for Alzheimer's disease imaging .
| Name | Position | External Roles | Short Bio | Start Date |
|---|---|---|---|---|
Brian Markison ExecutiveBoard | Chief Executive Officer (CEO) | Director of RVL Pharmaceuticals plc, Cosette Pharmaceuticals, and The College of New Jersey. | Over 40 years of pharmaceutical industry experience; previously Chairperson of LNTH Board and CEO of King Pharmaceuticals. | March 1, 2024 |
Amanda Morgan Executive | Chief Commercial Officer (CCO) | None | Joined LNTH in 2022; promoted to CCO in 2024; previously Chief Revenue and Customer Officer at Acadia Pharmaceuticals. | March 25, 2024 |
Daniel M. Niedzwiecki Executive | Chief Administrative Officer, General Counsel, and Corporate Secretary | None | Over 20 years of legal and business experience; joined LNTH in 2013 and oversees legal, compliance, HR, and communications. | March 2023 |
Dr. Jean-Claude Provost Executive | Chief Science Officer (CSO) | Board Member of the Centre for Probe Development and Commercialization (CPDC). | Over 30 years of experience in radiopharmaceuticals; transitioned from CMO to CSO in 2024. | May 28, 2024 |
Etienne Montagut Executive | Chief Business Officer (CBO) | None | Joined LNTH in 2018; led key collaborations, including the POINT Biopharma partnership. | September 2018 |
Paul M. Blanchfield Executive | President | None | Former Chief Commercial Officer and Chief Operating Officer at LNTH; led the successful launch of PYLARIFY. | March 20, 2023 |
Robert J. Marshall Jr. Executive | Chief Financial Officer (CFO) | None | Over 30 years of finance experience; previously held senior roles at Zimmer Biomet Holdings, Inc.. | September 2018 |
Dr. James H. Thrall Board | Director | None | Distinguished Juan M. Taveras Professor of Radiology at Harvard Medical School; former Chair of Radiology at Massachusetts General Hospital. | February 2018 |
Gary J. Pruden Board | Director | Board Member at Motus GI Holdings, Ossio Inc., Avisi Technologies, and Olympus Corporation. | Over 30 years of experience in the healthcare industry; former senior executive at Johnson & Johnson. | February 2018 |
Gérard Ber Board | Director | Board Member at Y-mAbs Therapeutics, Inc. and Evergreen Theragnostics. | Over 30 years of experience in molecular nuclear medicine; expertise in product development and commercialization. | June 2020 |
Heinz Mäusli Board | Director | Board Member at Inventiva SA. | Over 15 years of experience in molecular nuclear medicine; financial and legal expertise. | June 2020 |
Julie Eastland Board | Director | Independent Director at Dynavax Technologies and Veana Therapeutics. | Former CEO of Harpoon Therapeutics; extensive financial and operational leadership in biotech. | September 3, 2024 |
Julie McHugh Board | Lead Independent Director | Chair of the Board at Ironwood Pharmaceuticals; Board Member at Evelo Biosciences and New Xellia Group A/S. | Former COO of Endo Health Solutions; extensive experience in pharmaceutical and biotech industries. | January 2017 |
Mary Anne Heino Board | Chair of the Board of Directors | Executive Committee of the Massachusetts Business Roundtable; Board of MassMEDIC. | Former CEO of LNTH (2015–2024); led LNTH's growth in radiopharmaceuticals and diagnostics. | March 1, 2024 |
Minnie Baylor-Henry Board | Director | Independent Director at Apyx Medical, Paratek Pharmaceuticals, and scPharmaceuticals. | Former Worldwide VP for Regulatory Affairs at Johnson & Johnson; extensive regulatory and compliance expertise. | March 2022 |
Samuel R. Leno Board | Director | Board Member at GCM Manufacturing. | Over 40 years of financial and operational leadership experience; Vietnam veteran. | May 2012 |
- Given the net price compression from strategic partnerships affecting PYLARIFY's Q3 revenues, how do you anticipate this price pressure impacting revenue growth in 2025, and do you expect similar pricing dynamics to continue?
- With the SPLASH study's OS results confounded by high patient crossover to PNT2002, what specific strategies are you considering to address this issue with the FDA, and how might this affect the regulatory timeline for PNT2002's approval?
- Considering the potential for CMS pricing adjustments and increasing competition for PYLARIFY, how confident are you in maintaining its blockbuster status in 2025 and sustaining long-term growth amidst net price compression from strategic partnerships?
- Can you elaborate on how MK-6240 and NAV-4694 will differentiate themselves from existing imaging agents and emerging blood tests in Alzheimer's diagnostics, and what substantiates your confidence in achieving the projected $1.5 billion market size by the end of the decade?
- With rising costs in materials, freight, and overhead partially offsetting gross margin improvements, what measures are you implementing to manage these costs and sustain or improve gross margins amid potential pricing pressures and increased R&D investments?
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Evergreen Theragnostics | 2025 | Lantheus acquired Evergreen Theragnostics with an upfront cash payment of $250 million and milestone payments up to $752.5 million, enhancing manufacturing capabilities and expanding its oncology pipeline with OCTEVY for neuroendocrine tumors. |
Life Molecular Imaging | 2025 | The acquisition of Life Molecular Imaging involved a $350 million upfront cash payment, up to $400 million in contingent earn-outs, and additional liabilities, strategically expanding the AD radiodiagnostic franchise through Neuraceq and bolstering global commercial capabilities. |
Meilleur Acquisition | 2024 | The Meilleur acquisition was an asset purchase for NAV-4694, a Phase 3 F-18 PET imaging agent for Alzheimer’s disease, with an upfront payment of approximately $32.9 million plus additional milestone payments, aligning with the company’s diagnostic advancement goals. |
Radiopharm Theranostics Limited Agreement | 2024 | This limited agreement secured exclusive global rights to two preclinical assets—a TROP2-targeted nanobody and an LRRC15-targeted monoclonal antibody (DUNP19)—for an upfront payment of $2.0 million plus milestone and potential equity investment components, broadening the oncology portfolio. |
Cerveau Technologies, Inc. | 2023 | The acquisition of Cerveau Technologies, Inc. for its MK-6240 asset involved a $35.0 million upfront payment, additional technology transfer fees, and significant milestone and sales payments to bolster Lantheus’s diagnostic imaging portfolio for Alzheimer’s disease. |
PNT-2002 License Agreement | 2022 | The PNT-2002 License Agreement with POINT Biopharma granted Lantheus Two exclusive worldwide rights (with limited exceptions) for co-developing a prostate-specific radiopharmaceutical, involving a $250 million upfront payment and up to $1.28 billion in sales milestones plus regulatory payments. |
PNT-2003 License Agreement | 2022 | The PNT-2003 License Agreement entered via Lantheus Three provided rights to co-develop a somatostatin receptor-targeted radioligand therapy for neuroendocrine tumors, with a $10 million upfront payment, additional milestone and sales payments, and a 15% royalty on net sales. |
Recent developments and announcements about LNTH.
Earnings
New Earnings (Q4 2024)
·Feb 26, 2025, 4:03 PMView full earnings summary →Lantheus projects double-digit revenue growth resuming in 2026, fueled by PYLARIFY ($1B franchise, $550–$600M FCF in 2025) and new launches. Despite low–mid single-digit 2025 net sales gains for PYLARIFY, high margins and broad coverage keep LNTH on a strong trajectory.
Press Releases
Press Release
·Feb 12, 2025, 1:49 AMView full press release →Lantheus will acquire Evergreen Theragnostics in an all-cash deal with an upfront $250M payment and up to $752.5M in milestones. The transaction enhances its integrated radiopharmaceutical manufacturing and expands its oncology pipeline with OCTEVY and PNT2003.